Enhanced shedding of extracellular vesicles from amoeboid prostate cancer cells Potential effects on the tumor microenvironment

Cancer Biology and Therapy

Volumn 15, Issue 4, 2014, Pages 409-418

  Kim, Jayoung ^a,b,c   Morley, Samantha ^b,c   Le, Minh ^b   Bedoret, Denis ^b   Umetsu, Dale T ^b   Di Vizio, Dolores ^a,b,c   Freeman, Michael R ^a,b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AKT1; Amoeboid; EMT; Extracellular vesicles; Immune cells; Microvesicles; miR125a; Prostate cancer

Indexed keywords

ANDROGEN; DIAPH3 PROTEIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MICRORNA; MICRORNA 125A; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; DIAPH3 PROTEIN, HUMAN; MIRN125 MICRORNA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; BIOLOGICAL FUNCTIONS; CANCER CELL; CELL INFILTRATION; CELL INVASION; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN LNCAP; CELLULAR SECRETION; CONTROLLED STUDY; ENZYME ACTIVATION; EXOSOME; EXTRACELLULAR VESICLE SHEDDING; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MACROPHAGE; MALE; MOLECULAR MECHANICS; MONONUCLEAR CELL; MOUSE; NONHUMAN; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA; TUMOR MICROENVIRONMENT; GENETICS; IMMUNOLOGY; MEMBRANE MICROPARTICLE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANDROGENS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL-DERIVED MICROPARTICLES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84896983675     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.27627     Document Type: Article

References (65)

1. Kalluri R, Weinberg RA. The basics of epithelialmesenchymal transition. J Clin Invest 2009; 119:1420-8; PMID:19487818; http://dx.doi.org/10.1172/JCI39104
2. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Bröcker EB, Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003; 160:267-77; PMID:12527751; http://dx.doi.org/10. 1083/jcb.200209006
3. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003; 5:711-9; PMID:12844144; http://dx.doi.org/10.1038/ncb1019
4. Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning model. J Cell Biol 2010; 188:11-9; PMID:19951899; http://dx.doi.org/10.1083/jcb. 200909003
5. Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, Wolf K, Canzonieri V, D'Andrea S, Zucchetto A, Friedl P, et al. Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell 2008; 19:2003-13; PMID:18305103; http://dx.doi.org/10.1091/mbc.E07-09-0894
6. Shea KF, Wells CM, Garner AP, Jones GE. ROCK1 and LIMK2 interact in spread but not blebbing cancer cells. PLoS One 2008; 3:e3398; PMID:18852895; http://dx.doi.org/10.1371/journal.pone.0003398
7. Yoshida K, Soldati T. Dissection of amoeboid movement into two mechanically distinct modes. J Cell Sci 2006; 119:3833-44; PMID:16926192; http://dx.doi.org/10.1242/jcs.03152
8. Eisenmann KM, Harris ES, Kitchen SM, Holman HA, Higgs HN, Alberts AS. Dia-interacting protein modulates formin-mediated actin assembly at the cell cortex. Curr Biol 2007; 17:579-91; PMID:17398099; http://dx.doi.org/10.1016/j. cub.2007.03.024
9. Fackler OT, Grosse R. Cell motility through plasma membrane blebbing. J Cell Biol 2008; 181:879-84; PMID:18541702; http://dx.doi.org/10.1083/jcb. 200802081
10. Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, et al. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol 2012; 181:1573-84; PMID:23022210; http://dx.doi.org/10.1016/j.ajpath. 2012.07.030
11. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 2012; 21(R1):R125-34; PMID:22872698; http://dx.doi.org/10.1093/hmg/ dds317
12. Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci 2010; 123:1603-11; PMID:20445011; http://dx.doi.org/10. 1242/jcs.064386
13. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, Oeh J, Modrusan Z, Bais C, Sampath D, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J 2012; 31:3513-23; PMID:22773185; http://dx.doi.org/10.1038/emboj.2012.183
14. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B, Camussi G. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007; 110:2440-8; PMID:17536014; http://dx.doi.org/10.1182/blood-2007-03-078709
15. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 2012; 109:E2110-6; PMID:22753494; http://dx.doi.org/10.1073/pnas.1209414109
16. Bebawy M, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, Grau GE. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 2009; 23:1643-9; PMID:19369960; http://dx.doi.org/10. 1038/leu.2009.76
17. Rak J, Guha A. Extracellular vesicles - vehicles that spread cancer genes. Bioessays 2012; 34:489-97; PMID:22442051; http://dx.doi.org/10.1002/bies. 201100169
18. Hager MH, Morley S, Bielenberg DR, Gao S, Morello M, Holcomb IN, Liu W, Mouneimne G, Demichelis F, Kim J, et al. DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med 2012; 4:743-60; PMID:22593025; http://dx.doi.org/10.1002/emmm.201200242
19. Goode BL, Eck MJ. Mechanism and function of formins in the control of actin assembly. Annu Rev Biochem 2007; 76:593-627; PMID:17373907; http://dx.doi.org/10.114 6/annurev.biochem.75.103004.142647
20. Breitsprecher D, Goode BL. Formins at a glance. J Cell Sci 2013; 126:1-7; PMID:23516326; http://dx.doi.org/10.1242/jcs.107250
21. Thurston SF, Kulacz WA, Shaikh S, Lee JM, Copeland JW. The ability to induce microtubule acetylation is a general feature of formin proteins. PLoS One 2012; 7:e48041; PMID:23110170; http://dx.doi.org/10.1371/journal.pone.0048041
22. Bartolini F, Gundersen GG. Formins and microtubules. Biochim Biophys Acta 2010; 1803:164-73; PMID:19631698; http://dx.doi.org/10.1016/j. bbamcr.2009.07.006
23. Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ, True LD, Rubin MA, Adam RM, Beroukhim R, et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res 2009; 69:5601-9; PMID:19549916; http://dx.doi.org/10.1158/ 0008-5472.CAN-08-3860
24. Freeman MR, Paul S, Kaefer M, Ishikawa M, Adam RM, Renshaw AA, Elenius K, Klagsbrun M. Heparin-binding EGF-like growth factor in the human prostate: synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. J Cell Biochem 1998; 68:328-38; PMID:9518259; http://dx.doi.org/10.1002/(SICI)1097-4644(19980301)68:3〈328: :AID-JCB4〉 3.0.CO;2-W
25. Kim J, Adam RM, Freeman MR. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res 2002; 62:1549-54; PMID:11888934
26. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999; 59:2891-7; PMID:10383151
27. Muralidharan-Chari V, Clancy J, Plou C, Romao M, Chavrier P, Raposo G, D'Souza-Schorey C. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol 2009; 19:1875-85; PMID:19896381; http://dx.doi.org/10. 1016/j.cub.2009.09.059
28. Kim J, Keay SK, Freeman MR. Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation. BJU Int 2009; 103:541-6; PMID:18990151; http://dx.doi.org/10.1111/j.1464-410X.2008.08097.x
29. Dong QZ, Wang Y, Tang ZP, Fu L, Li QC, Wang ED, Wang EH. Derlin-1 is overexpressed in nonsmall cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am J Pathol 2013; 182:954-64; PMID:23306155; http://dx.doi.org/10.1016/j.ajpath.2012.11.019
30. Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou HF, Guo L, Liu W, Wang SJ, Yu XG. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 2012; 40:1714-24; PMID:22200661
31. Li B, Antonyak MA, Zhang J, Cerione RA. RhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells. Oncogene 2012; 31:4740-9; PMID:22266864; http://dx.doi.org/10.1038/onc.2011.636
32. Wegiel B, Evans S, Hellsten R, Otterbein LE, Bjartell A, Persson JL. Molecular pathways in the progression of hormone-independent and metastatic prostate cancer. Curr Cancer Drug Targets 2010; 10:392-401; PMID:20384583; http://dx.doi.org/10.2174/156800910791208562
33. Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z, Hu G, Yang Q. MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. Oncogene 2013; (Forthcoming); PMID:23851509; http://dx.doi.org/10.1038/onc.2013.286
34. Valastyan S. Roles of microRNAs and other non-coding RNAs in breast cancer metastasis. J Mammary Gland Biol Neoplasia 2012; 17:23-32; PMID:22293951; http://dx.doi.org/10.1007/s10911-012-9241-9
35. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010; 11:252-63; PMID:20216554; http://dx.doi.org/10.1038/ nrm2868
36. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR, Sarkar FH. miR-200 regulates PDGF-D- mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009; 27:1712-21; PMID:19544444; http://dx.doi.org/10.1002/stem.101
37. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ, deVere White RW. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 2007; 104:19983-8; PMID:18056640; http://dx.doi.org/10.1073/pnas. 0706641104
38. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 2011; 71:538-49; PMID:20886540; http://dx.doi.org/10.1002/pros.21270
39. Duque JL, Adam RM, Mullen JS, Lin J, Richie JP, Freeman MR. Heparin-binding epidermal growth factor-like growth factor is an autocrine mediator of human prostate stromal cell growth in vitro. J Urol 2001; 165:284-8; PMID:11125426; http://dx.doi.org/10.1097/00005392-200101000-00080
40. Lee TH, D'Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J. Microvesicles as mediators of intercellular communication in cancer - the emerging science of cellular 'debris'. Semin Immunopathol 2011; 33:455-67; PMID:21318413; http://dx.doi.org/10.1007/s00281-011-0250-3
41. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008; 10:619-24; PMID:18425114; http://dx.doi.org/10.1038/ncb1725
42. Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A 2009; 106:3794-9; PMID:19234131; http://dx.doi.org/10.1073/pnas.0804543106
43. Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, Skog J. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2011; 2:180; PMID:21285958; http://dx.doi.org/10.1038/ ncomms1180
44. Noerholm M, Balaj L, Limperg T, Salehi A, Zhu LD, Hochberg FH, Breakefield XO, Carter BS, Skog J. RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls. BMC Cancer 2012; 12:22; PMID:22251860; http://dx.doi.org/10.1186/1471-2407-12-22
45. Camussi G, Deregibus MC, Tetta C. Tumor-derived microvesicles and the cancer microenvironment. Curr Mol Med 2013; 13:58-67; PMID:22834836; http://dx.doi.org/10.2174/156652413804486304
46. D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev 2012; 26:1287-99; PMID:22713869; http://dx.doi.org/10.1101/gad.192351.112
47. Filipazzi P, Bürdek M, Villa A, Rivoltini L, Huber V. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol 2012; 22:342-9; PMID:22369922; http://dx.doi.org/10.1016/j.semcancer.2012.02.005
48. Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18:883-91; PMID:22635005; http://dx.doi.org/10.1038/nm.2753
49. Hannemann S, Madrid R, Stastna J, Kitzing T, Gasteier J, Schönichen A, Bouchet J, Jimenez A, Geyer M, Grosse R, et al. The Diaphanous-related Formin FHOD1 associates with ROCK1 and promotes Src-dependent plasma membrane blebbing. J Biol Chem 2008; 283:27891-903; PMID:18694941; http://dx.doi.org/10. 1074/jbc.M801800200
50. Kitzing TM, Sahadevan AS, Brandt DT, Knieling H, Hannemann S, Fackler OT, Grosshans J, Grosse R. Positive feedback between Dia1, LARG, and RhoA regulates cell morphology and invasion. Genes Dev 2007; 21:1478-83; PMID:17575049; http://dx.doi.org/10.1101/gad.424807
51. Kitzing TM, Wang Y, Pertz O, Copeland JW, Grosse R. Formin-like 2 drives amoeboid invasive cell motility downstream of RhoC. Oncogene 2010; 29:2441-8; PMID:20101212; http://dx.doi.org/10.1038/onc.2009.515
52. Wyse MM, Lei J, Nestor-Kalinoski AL, Eisenmann KM. Dia-interacting protein (DIP) imposes migratory plasticity in mDia2-dependent tumor cells in three-dimensional matrices. PLoS One 2012; 7:e45085; PMID:23024796; http://dx.doi.org/10.1371/journal.pone.0045085
53. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593-601; PMID:18376396; http://dx.doi.org/10.1038/ncb1722
54. Elson-Schwab I, Lorentzen A, Marshall CJ. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS One 2010; 5:e13176; PMID:20957176; http://dx.doi.org/10.1371/ journal.pone.0013176
55. Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microRNA Profiling of Prostate Cancer. J Cancer 2013; 4:350-7; PMID:23781281; http://dx.doi.org/10.7150/jca.6394
56. Sun D, Zhuang X, Xiang X, Liu Y, Zhang S, Liu C, Barnes S, Grizzle W, Miller D, Zhang HG. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 2010; 18:1606-14; PMID:20571541; http://dx.doi.org/10.1038/ mt.2010.105
57. van Dommelen SM, Vader P, Lakhal S, Kooijmans SA, van Solinge WW, Wood MJ, Schiffelers RM. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J Control Release 2012; 161:635-44; PMID:22138068; http://dx.doi.org/10.1016/j.jconrel.2011.11.021
58. EL Andaloussi S, Mäger I, Breakefield XO, Wood MJ; S ELA. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013; 12:347-57; PMID:23584393; http://dx.doi.org/10.1038/nrd3978
59. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006; 1:297-315; PMID:17717971
60. Kooijmans SA, Vader P, van Dommelen SM, van Solinge WW, Schiffelers RM. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine 2012; 7:1525-41; PMID:22619510
61. Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 2013; 41:245-51; PMID:23356291; http://dx.doi.org/10.1042/BST20120265
62. Kim J, Kim WJ, Liu Z, Loda M, Freeman MR. The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle 2012; 11:1123-30; PMID:22370483; http://dx.doi.org/10.4161/cc.11.6.19550
63. Mukhopadhyay NK, Kim J, Cinar B, Ramachandran A, Hager MH, Di Vizio D, Adam RM, Rubin MA, Raychaudhuri P, De Benedetti A, et al. Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res 2009; 69:2210-8; PMID:19258514; http://dx.doi.org/10.1158/0008-5472. CAN-08-2308
64. Kim J, Jahng WJ, Di Vizio D, Lee JS, Jhaveri R, Rubin MA, Shisheva A, Freeman MR. The phosphoinositide kinase PIKfyve mediates epidermal growth factor receptor trafficking to the nucleus. Cancer Res 2007; 67:9229-37; PMID:17909029; http://dx.doi.org/10.1158/0008-5472.CAN-07-1333
65. Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, DeKruyff RH, Schneider LC, Nadeau KC, Umetsu DT. Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol 2012; 5:267-76; PMID:22318492; http://dx.doi.org/10. 1038/mi.2012.5